The forecast for Calcium Channel Blocking Medicine sales in Canada indicates a consistent decline from 2024 to 2028. The data shows a year-on-year decrease, with sales dropping from $290.8 million in 2024 to $226.6 million by 2028. In 2023, the sales stood at approximately the same level as in 2024, indicating the start of the decline from a stable base. The compound annual growth rate (CAGR) over these five years suggests a significant downward trend in sales.
Future trends to watch for include potential impacts of new therapies that could replace calcium channel blockers, changes in healthcare policies, and the market entry of generic alternatives driving competition. Monitoring advancements in medical research and shifts in prescribing practices will be vital in forecasting future market dynamics.
